Stockscreener 앱 받기
34.11
3.23%
-1.14
시장 영업 전:
35.00
0.89
+2.61%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com Australia
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics: Q2 Earnings Snapshot - San Francisco Chronicle
CYTOKINETICS INC SEC 10-Q Report - TradingView
Cytokinetics Inc earnings beat by $0.30, revenue topped estimates - Investing.com Australia
Cytokinetics Earnings Surge: Revenue Jumps to $66.8M with FDA Decision on Key Drug Coming December - Stock Titan
ATTENTION Cytokinetics, Incorporated Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Federated Hermes Inc. Has $1.37 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
TR | OpenAI4o Initiates Cytokinetics(CYTK.US) With Hold Rating, Announces Target Price $37 - 富途牛牛
Top Executive Sells Thousands in Cytokinetics Stock! - TipRanks
Malik, Cytokinetics EVP, sells $72,680 in shares By Investing.com - Investing.com Canada
Malik, Cytokinetics EVP, sells $72,680 in shares - Investing.com
Cytokinetics EVP Research & Development Malik Fady Ibraham Buys 2000 Shares at $10.6/Share, Sells 2000 Shares at $36.34/Share. - AInvest
Spinal Muscular Atrophy Market Opportunities and Future Scope - openPR.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Assetmark Inc. - Defense World
Published on: 2025-08-04 22:46:47 - metal.it
Cytokinetics Incorporated Price Holds Above Key Fib LevelAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Why Cytokinetics Incorporated stock attracts strong analyst attentionSwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsOutstanding capital growth - Jammu Links News
How strong is Cytokinetics Incorporated company’s balance sheetBuild a diversified portfolio for risk management - Jammu Links News
Cytokinetics Incorporated Stock Analysis and ForecastBuild wealth with long-term growth strategies - Jammu Links News
What makes Cytokinetics Incorporated stock price move sharplyCapitalize on emerging industry trends - Jammu Links News
What is Cytokinetics Incorporated company’s growth strategyMarket-leading capital gains - Jammu Links News
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Raymond James Financial - MarketBeat
What catalysts could drive Cytokinetics Incorporated stock higher in 2025Build a winning investment portfolio - Jammu Links News
Should I hold or sell Cytokinetics Incorporated stock in 2025Rapid growth opportunities - Jammu Links News
What are the latest earnings results for Cytokinetics IncorporatedExpert Picks Outlook For Beginners - jammulinksnews.com
Watch for Trend Continuation in Cytokinetics Incorporated Next WeekSwing Trading Plan With Smart Signals in Review - beatles.ru
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
What institutional investors are buying Cytokinetics Incorporated stockFree Stock Forecasts That Work - jammulinksnews.com
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Institutional Tools Highlight Unusual Flow in Cytokinetics IncorporatedWeekly Chart Analysis With Entry Advice Provided - metal.it
Raymond James downgrades Cytokinetics stock rating to Market Perform By Investing.com - Investing.com Canada
Cytokinetics, Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Support and Resistance Levels You Should KnowRisk Controlled Picks With Real Returns Outlined - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):